Actively Recruiting

Phase Not Applicable
Age: 35Years - 79Years
All Genders
NCT06828692

Implementation of Machine Learning and Hemodynamic Profiles Based Clinical Decision Support Systems for Personalized Guideline Accordant Antihypertensive Regimens in Primary Care: a Pragmatic Cluster Randomized Controlled Trial

Led by China National Center for Cardiovascular Diseases · Updated on 2026-02-12

2160

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This trial is a prospective, multicenter, single-blind, three-arm parallel-group, cluster randomized controlled trial assessing the effectiveness and safety of two types of CDSS in primary care settings in China. Primary care sites are randomized to one of the intervention arms or the control arm (1:1:1 ratio) using computer-generated random numbers stratified by region and administrative categories of the primary healthcare institutions (including community health centers, community health stations, and township health centers). A total of 51 primary care sites are randomized to three groups, with 17 sites assigned to group A (use a CDSS based on clinical guidelines and machine learning), 17 sites to group B (use a CDSS based on guidelines, hemodynamic parameters and ML), and the remaining 17 sites to the control group.

CONDITIONS

Official Title

Implementation of Machine Learning and Hemodynamic Profiles Based Clinical Decision Support Systems for Personalized Guideline Accordant Antihypertensive Regimens in Primary Care: a Pragmatic Cluster Randomized Controlled Trial

Who Can Participate

Age: 35Years - 79Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 35 and less than 80 years
  • Regularly attend the clinic for hypertension treatment during the study period without plans to travel
  • Diagnosed with hypertension with systolic blood pressure (SBP) 140 mmHg or higher at screening
  • Currently taking zero or up to two classes of antihypertensive medications (A/C/D), with or without concurrent use of class B
  • Willing to participate and able to provide written informed consent
Not Eligible

You will not qualify if you...

  • Diagnosed or suspected secondary hypertension due to specific medical conditions
  • Systolic blood pressure 180 mmHg or higher and/or diastolic blood pressure 110 mmHg or higher at screening
  • Suspected or diagnosed white coat hypertension
  • History of coronary heart disease
  • History of heart failure
  • Intolerance to two or more classes of A, C, D antihypertensive medications
  • Currently taking antihypertensive medications other than classes A, B, C, or D
  • Diagnosed chronic kidney disease with eGFR less than 60 ml/min/1.73m2 or on dialysis
  • Serious medical conditions such as malignant cancer or liver dysfunction
  • Currently in an acute episode of disease within the last 3 months
  • Cognitive or communicative disorders
  • Currently pregnant, breastfeeding, or planning pregnancy or breastfeeding during the study
  • Reluctant to take antihypertensive medications or poor compliance with previous treatment
  • Participating in other clinical trials

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences

Shenzhen, Shenzhen, China

Actively Recruiting

Loading map...

Research Team

X

Xiaofang Yan

CONTACT

X

Xin Zheng

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here